Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Cost-Benefit Analysis; Humans; Interferon Type I, Recombinant; Multiple Sclerosis; Peptides; Quality-Adjusted Life Years; United States

AccessionNumber
22009102516

Date bibliographic record published
07/10/2009